Immix Biopharma Inc (NASDAQ:IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE:BGNE) / Novartis AG’s (NYSE:NVS) tislelizumab, for advanced solid tumors.
100% Tumor Shrinkage at two months was observed in advanced metastatic colorectal cancer demonstrated by IMX-110 + tislelizumab combination in the first cohort of patients who received the lowest IMX-110 dose.
Tumor shrinkage was observed in the first two out of two (2/2) evaluable patients (100%) at two months.
The company compares the data with Merck & Co Inc’s (NYSE:MRK) anti-PD-1 antibody Keytruda (pembrolizumab) alone produced tumor shrinkage in 3 of 19 patients (16%) with an evaluable postbaseline tumor assessment in Phase 1b study of pembrolizumab in patients with advanced or metastatic colorectal cancer according to O’Neil et al., 2017.
No dose-limiting toxicities have been observed in the first cohort. Hence the trial can now enroll the next cohort of three patients at a higher dose of IMX-110 + tislelizumab.
Immix Biopharma is enrolling the next higher dose cohort of IMX-110 + anti-PD-1 antibody tislelizumab in advanced solid tumors.
Price Action: IMMX shares are down 5.17 at $2.75 on the last check Wednesday.
